MiR-873 regulates ERα transcriptional activity and tamoxifen resistance via targeting CDK3 in breast cancer cells

Oncogene

Volumn 34, Issue 30, 2015, Pages 3895-3907

  Cui, J ^a   Yang, Y ^b   Li, H ^c   Leng, Y ^d   Qian, K ^d   Huang, Q ^e   Zhang, C ^a,f   Lu, Z ^a   Chen, J ^g   Sun, T ^g   Wu, R ^a   Sun, Y ^a   Song, H ^a   Wei, X ^h   Jing, P ⁱ   Yang, X ^j  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF KENTUCKY   (United States)

^d JIUJIANG UNIVERSITY   (China)

^e JILIN AGRICULTURAL UNIVERSITY   (China)

^f CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^g NANCHANG UNIVERSITY   (China)

^h PEKING UNIVERSITY   (China)

ⁱ PURDUE UNIVERSITY FORT WAYNE   (United States)

^j ANHUI UNIVERSITY   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 3; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; MESSENGER RNA; MICRORNA; MICRORNA 873; TAMOXIFEN; UNCLASSIFIED DRUG; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CDK3 PROTEIN, HUMAN; ESTROGEN RECEPTOR ALPHA, HUMAN; MIRN873 MICRORNA, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LUCIFERASE ASSAY; MOUSE; MTT ASSAY; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR GROWTH; WESTERN BLOTTING; ANIMAL; BINDING SITE; BREAST NEOPLASMS; DRUG RESISTANCE; DRUG SCREENING; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; MCF 7 CELL LINE; METABOLISM; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN PROCESSING; RNA INTERFERENCE; TRANSCRIPTION INITIATION;

MUS MUSCULUS;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BASE SEQUENCE; BINDING SITES; BREAST NEOPLASMS; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE 3; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; MICE, NUDE; MICRORNAS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RNA INTERFERENCE; TAMOXIFEN; TRANSCRIPTIONAL ACTIVATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84937969295     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.430     Document Type: Article

References (55)

1. Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med 2001; 344: 276-285.
2. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006; 354: 270-282.
3. Thomas C, Gustafsson JA. The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer 2011; 11: 597-608.
4. Klinge CM. Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res 2001; 29: 2905-2919.
5. Green KA, Carroll JS. Oestrogen-receptor-mediated transcription and the influence of co-factors and chromatin state. Nat Rev Cancer 2007; 7: 713-722.
6. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998; 95: 927-937.
7. Tyson JJ, Baumann WT, Chen C, Verdugo A, Tavassoly I, Wang Y et al. Dynamic modelling of oestrogen signalling and cell fate in breast cancer cells. Nat Rev Cancer 2011; 11: 523-532.
8. Kim K, Thu N, Saville B, Safe S. Domains of estrogen receptor alpha (ERalpha) required for ERalpha/Sp1-mediated activation of GC-rich promoters by estrogens and antiestrogens in breast cancer cells. Mol Endocrinol 2003; 17: 804-817.
9. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997; 389: 753-758.
10. Smith CL, Nawaz Z, O'Malley BW. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol 1997; 11: 657-666.
11. Shang Y, Brown M. Molecular determinants for the tissue specificity of SERMs. Science 2002; 295: 2465-2468.
12. Manavathi B, Dey O, Gajulapalli VNR, Bhatia RS, Bugide S, Kumar R. Derailed estrogen signaling and breast cancer: An authentic couple. Endocrine Reviews 2013; 34: 1-32.
13. Nilsson S, Koehler KF, Gustafsson JA. Development of subtype-selective oestrogen receptor-based therapeutics. Nat Rev Drug Discov 2011; 10: 778-792.
14. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators-mechanisms of action and application to clinical practice. N Engl J Med 2003; 348: 618-629.
15. Abe O, Abe R, Enomoto K, Kikuchi K, Koyama H, Masuda H et al. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005; 365: 1687-1717.
16. McCartan D, Bolger JC, Fagan A, Byrne C, Hao Y, Qin L et al. Global characterization of the SRC-1 transcriptome identifies ADAM22 as an ER-independent mediator of endocrine-resistant breast cancer. Cancer Res 2012; 72: 220-229.
17. Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2002; 2: 101-112.
18. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/ HER2-positive breast cancer. J Natl Cancer Inst 2004; 96: 926-935.
19. Osborne CK, Shou J, Massarweh S, Schiff R. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 2005; 11: 865s-870s.
20. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 2011; 62: 233-247.
21. Wardell SE, Nelson ER, Chao CA, McDonnell DP. Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease. Clin Cancer Res 2013; 19: 2420-2431.
22. Mulrane L, McGee SF, Gallagher WM, O'Connor DP. miRNA dysregulation in breast cancer. Cancer Res 2013; 73: 6554-6562.
23. Nana-Sinkam SP, Croce CM. Clinical applications for microRNAs in cancer. Clin Pharmacol Ther 2013; 93: 98-104.
24. Dvinge H, Git A, Graf S, Salmon-Divon M, Curtis C, Sottoriva A et al. The shaping and functional consequences of the microRNA landscape in breast cancer. Nature 2013; 497: 378-382.
25. Klinge CM. miRNAs and estrogen action. Trends Endocrinol Metab 2012; 23: 223-233.
26. Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro CL et al. MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem 2008; 283: 29897-29903.
27. Ward A, Balwierz A, Zhang JD, Kublbeck M, Pawitan Y, Hielscher T et al. Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer. Oncogene 2013; 32: 1173-1182.
28. Suzuki H, Takatsuka S, Akashi H, Yamamoto E, Nojima M, Maruyama R et al. Genome-wide profiling of chromatin signatures reveals epigenetic regulation of MicroRNA genes in colorectal cancer. Cancer Res 2011; 71: 5646-5658.
29. Skalsky RL, Cullen BR. Reduced expression of brain-enriched microRNAs in glioblastomas permits targeted regulation of a cell death gene. PLoS ONE 2011; 6: e24248.
30. Zhang L, Volinia S, Bonome T, Calin GA, Greshock J, Yang N et al. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci USA 2008; 105: 7004-7009.
31. Trowbridge JM, Rogatsky I, Garabedian MJ. Regulation of estrogen receptor transcriptional enhancement by the cyclin A/Cdk2 complex. Proc Natl Acad Sci USA 1997; 94: 10132-10137.
32. Zheng D, Cho YY, Lau AT, Zhang J, Ma WY, Bode AM et al. Cyclin-dependent kinase 3-mediated activating transcription factor 1 phosphorylation enhances cell transformation. Cancer Res 2008; 68: 7650-7660.
33. Wesierska-Gadek J, Gritsch D, Zulehner N, Komina O, Maurer M. Roscovitine, a selective CDK inhibitor, reduces the basal and estrogen-induced phosphorylation of ER-alpha in human ER-positive breast cancer cells. J Cell Biochem 2011; 112: 761-772.
34. Hoffman JT, O'Gorman M, Loi C, Plotka A, Kirkovsky L, Boutros T et al. 76p∗a phase 1 open-label fixed-sequence two-period crossover study of the effect of multiple doses of tamoxifen on palbociclib (pd-0332991) pharmacokinetics in healthy male volunteers. Ann Oncol 2014; 25(Suppl 1): i27.
35. Cui J, Germer K, Wu T, Wang J, Luo J, Wang SC et al. Cross-talk between HER2 and MED1 regulates tamoxifen resistance of human breast cancer cells. Cancer Res 2012; 72: 5625-5634.
36. Keeton EK, Brown M. Cell cycle progression stimulated by tamoxifen-bound estrogen receptor-alpha and promoter-specific effects in breast cancer cells deficient in N-CoR and SMRT. Mol Endocrinol 2005; 19: 1543-1554.
37. Sun X, Jiao X, Pestell TG, Fan C, Qin S, Mirabelli E et al. MicroRNAs and cancer stem cells: The sword and the shield. Oncogene 2013; 33: 4967-4977.
38. Tian W, Chen J, He H, Deng Y. MicroRNAs and drug resistance of breast cancer: basic evidence and clinical applications. Clin Transl Oncol 2013; 15: 335-342.
39. Song SJ, Poliseno L, Song MS, Ala U, Webster K, Ng C et al. MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling. Cell 2013; 154: 311-324.
40. Bergamaschi A, Katzenellenbogen BS. Tamoxifen downregulation of miR-451 increases 14-3-3zeta and promotes breast cancer cell survival and endocrine resistance. Oncogene 2012; 31: 39-47.
41. de Leeuw R, Neefjes J, Michalides R. A role for estrogen receptor phosphorylation in the resistance to tamoxifen. Int J Breast Cancer 2011; 2011: 232435.
42. Kok M, Holm-Wigerup C, Hauptmann M, Michalides R, Stal O, Linn S et al. Estrogen receptor-alpha phosphorylation at serine-118 and tamoxifen response in breast cancer. J Natl Cancer Inst 2009; 101: 1725-1729.
43. Vendrell JA, Bieche I, Desmetz C, Badia E, Tozlu S, Nguyen C et al. Molecular changes associated with the agonist activity of hydroxy-tamoxifen and the hyperresponse to estradiol in hydroxy-tamoxifen-resistant breast cancer cell lines. Endocr Relat Cancer 2005; 12: 75-92.
44. Sarwar N, Kim JS, Jiang J, Peston D, Sinnett HD, Madden P et al. Phosphorylation of ER alpha at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ER alpha phosphorylation in breast cancer progression. Endocr-Relat Cancer 2006; 13: 851-861.
45. Likhite VS, Stossi F, Kim K, Katzenellenbogen BS, Katzenellenbogen JA. Kinasespecific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity. Mol Endocrinol 2006; 20: 3120-3132.
46. Ren S, Rollins BJ. Cyclin C/cdk3 promotes Rb-dependent G0 exit. Cell 2004; 117: 239-251.
47. Sutherland RL, Musgrove EA. CDK inhibitors as potential breast cancer therapeutics: new evidence for enhanced efficacy in ER+ disease. Breast Cancer Res 2009; 11: 112.
48. Cicenas J, Valius M. The CDK inhibitors in cancer research and therapy. J Cancer Res Clin Oncol 2011; 137: 1409-1418.
49. Ye X, Zhu C, Harper JW. A premature-termination mutation in the Mus musculus cyclin-dependent kinase 3 gene. Proc Natl Acad Sci USA 2001; 98: 1682-1686.
50. Wang L, Hu HY, Lin YL, Zhao ZX, Tan L, Yu P et al. CDK3 expression and its clinical significance in human nasopharyngeal carcinoma. Mol Med Rep 2014; 9: 2582-2586.
51. Bullrich F, MacLachlan TK, Sang N, Druck T, Veronese ML, Allen SL et al. Chromosomal mapping of members of the cdc2 family of protein kinases, cdk3, cdk6, PISSLRE, and PITALRE, and a cdk inhibitor, p27Kip1, to regions involved in human cancer. Cancer Res 1995; 55: 1199-1205.
52. Zhang D, Jiang P, Xu Q, Zhang X. Arginine and glutamate-rich 1 (ARGLU1) interacts with mediator subunit 1 (MED1) and is required for estrogen receptormediated gene transcription and breast cancer cell growth. J Biol Chem 2011; 286: 17746-17754.
53. Shang YF, Hu X, DiRenzo J, Lazar MA, Brown M. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 2000; 103: 843-852.
54. Cui J, Yang Y, Zhang C, Hu P, Kan W, Bai X et al. FBI-1 functions as a novel AR corepressor in prostate cancer cells. Cell Mol Life Sci 2011; 68: 1091-1103.
55. Cho YY, Tang F, Yao K, Lu C, Zhu F, Zheng D et al. Cyclin-dependent kinase-3-mediated c-Jun phosphorylation at Ser63 and Ser73 enhances cell transformation. Cancer Res 2009; 69: 272-281.